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Abstract
DNA methylation is one of the most studied epigenetic marks in the human genome, with the result that the desire to map
the human methylome has driven the development of several methods to map DNA methylation on a genomic scale. Our
study presents the first comparison of two of these techniques - the targeted approach of the Infinium
HumanMethylation450 BeadChipH with the immunoprecipitation and sequencing-based method, MeDIP-seq. Both
methods were initially validated with respect to bisulfite sequencing as the gold standard and then assessed in terms of
coverage, resolution and accuracy. The regions of the methylome that can be assayed by both methods and those that can
only be assayed by one method were determined and the discovery of differentially methylated regions (DMRs) by both
techniques was examined. Our results show that the Infinium HumanMethylation450 BeadChipH and MeDIP-seq show a
good positive correlation (Spearman correlation of 0.68) on a genome-wide scale and can both be used successfully to
determine differentially methylated loci in RefSeq genes, CpG islands, shores and shelves. MeDIP-seq however, allows a
wider interrogation of methylated regions of the human genome, including thousands of non-RefSeq genes and repetitive
elements, all of which may be of importance in disease. In our study MeDIP-seq allowed the detection of 15,709
differentially methylated regions, nearly twice as many as the array-based method (8070), which may result in a more
comprehensive study of the methylome.
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Introduction
DNA methylation is one of the most studied epigenetic marks in
the human genome involving the covalent addition of a methyl
group to the fifth carbon of cytosine residues predominantly within
the context of CpG dinucleotides. Patterns of DNA methylation
are determined in early development [1], are heritable [2] and
stably maintained through cell division but can also be dynamic in
response to environment [3]. Changes in methylation patterns are
an essential mechanism used to control many biological processes
including gene regulation, X chromosome inactivation, genomic
imprinting and cellular differentiation. There is an ever increasing
list of diseases, including a wide variety of cancers [4], in which
alterations in DNA methylation patterns can be demonstrated to
be either a causal factor in, or a consequence of disease [5,6]. A
complete characterisation of the methylome and the dynamic
changes that occur within it may in some cases serve as an
accurate predictor of prognosis and treatment success [7].
The desire to map the entire methylome has driven the
development of large-scale DNA methylation profiling methods.
Bisulfite sequencing is generally accepted as the ‘gold standard’
method for detection of DNA methylation [8] providing highly
accurate single nucleotide resolution. Combined with second-
generation high-throughput sequencing technologies bisulfite
sequencing is arguably the best approach to provide the complete
methylome [9,10,11]. Bisulfite sequencing alone, however, does
not distinguish between 5-methylcytosine (5mC) and 5-hydro-
xymethylcytosine (5hmC). The recently published oxidative
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bisulfite sequencing (oxBS-Seq) [12] and Tet-assisted bisulfite
sequencing (TAB-Seq) methods [13] both enable this distinction
and allow mapping of 5hmC to single nucleotide resolution.
However, despite the important and welcome advance, they are
both still reliant on bisulfite sequencing and hence are prohibi-
tively costly for the larger genomes when applied genome-wide
and therefore may not be the appropriate and practical method of
choice for large numbers of samples.
Several methods have been developed that are more applicable
on a large-scale. Driven by the need to understand the strengths
and limitations of each of these methods, there have been a
number of comparison papers published [14,15,16,17] which have
included systematic assessments of six sequencing based technol-
ogies and one array based method: whole genome bisulfite
sequencing (WGBS) [18,19,20], reduced representation bisulfite
sequencing (RRBS) [21,22], MethylC-seq [20], methylated DNA
immunoprecipitation sequencing (MeDIP-seq) [23,24], methylat-
ed DNA capture by affinity purification (MethylCap-seq) [25],
methylated DNA binding domain sequencing (MBD-seq) [26] and
Infinium HumanMethylation27 BeadChipH (HumanMethylation
27K) [27]. The general conclusion from these comparisons was
that although all of the techniques are capable of producing
accurate data with reasonable concordance, there is no overall
recommendation for any one technique and the choice of method
will depend on the research question being asked, the sample
numbers, cost and through-put required.
Recently Illumina have released the Infinium HumanMethyla-
tion450 BeadChipH (HumanMethylation 450K). This new array,
which interrogates over 480,000 of the 28 million CpG sites in the
human methylome, covers over 17-fold more CpG sites than its
predecessor the HumanMethylation 27K and therefore enables a
more comprehensive sampling of the methylome [28,29,30]. The
HumanMethylation 450K array was designed to provide 96%
coverage of known CpG islands (based on UCSC classifications)
[31,32], 99% of RefSeq genes [33] and many other features.
Reports have been published comparing the HumanMethylation
450K with the HumanMethylation 27K [29] and whole genome
bisulfite sequencing [28,30] which have shown the data produced
to be both reproducible and highly accurate. The expanded
number of targets makes the HumanMethylation 450K array a
potentially attractive choice when considering large sample
numbers and cost.
MeDIP-seq uses immunoprecipitation to enrich for the portion
of the genome containing either 5-methylcytosine (5mC) or the
hydroxymethylated form, 5-hydroxymethylcytosine (5hmC) de-
pending on the antibody used, followed by high-throughput
sequencing [23,24,34]. MeDIP-seq provides genome-wide cover-
age and was used to generate the first whole-genome methylation
profile of a mammalian genome [24]. It has since been successfully
used to provide methylation profiles of several tissues including
human breast cancer cells [35], peripheral blood mononucleocytes
(PBMCs) [16] and benign and malignant nerve tumours [36].
Our study presents the first comparison of the targeted
approach of the Infinium HumanMethylation450 BeadChipH
with MeDIP-seq. The strengths and limitations of each method, in
terms of coverage, resolution and accuracy will be explored, and
regions of the methylome that can be assayed by both methods
and those that are only assayed by one method determined.
Discovery of differentially methylated regions by both techniques
will also be examined.
Results
We have designed a study to compare the targeted approach of
the Infinium HumanMethylation450 BeadChipH with a genome-
wide method, MeDIP-seq, in order to assess and compare the
ability of each method to assay the methylome (Figure S1). The
two methods were compared using DNA from two cell lines:
GM01240 (XX) and GM01247 (XY), a sibling pair of European
descent (see Methods), generating a total of four methylation
profiles for analysis. Two different methods of analysis were tested
per technique. On the basis of these results (data not shown), for
this study, the HumanMethylation 450K data was analysed using
GenomeStudio and custom-written scripts, and the MeDIP-seq
data using MEDIPS (see Methods). In addition, a subset of data
from each methylation profile was validated by comparison to
clonal bisulfite sequencing data (used as the gold standard) from 34
CpG islands on the human X chromosome.
DNA methylation profiles were generated using the Illumina
InfiniumH HumanMethylation450 BeadChipH and MeDIP-seq
for the two cell lines, GM01240 and GM01247 as described (see
Methods). MeDIP was performed on a DNA sample from each
cell line using the Methylated-DNA IP kit (Zymo Research) (see
Methods). The resultant paired-end libraries were sequenced to
saturation on one lane of an Illumina HiSeq 2000 using 75 cycles
(see Figure S2 for saturation curve and Table S5 for sequencing
statistics). This resulted in 240 M reads (18 Gb) for sample
GM01240, 190 M of which were mapped with a mapping quality
score of $10, and 234 M reads (17.6 Gb) for sample GM01247,
181 M of which mapped with a mapping quality score of $10.
The amount of sequence data generated in our study has given an
average read depth of 9.56 and 9.41 over all CpG sites in the
human genome for GM01240 and GM01247 respectively. The
percentage of genomic CpG sites covered by our data at different
fold coverage is shown in Figure S3.
In order to evaluate how much of the genome (and methylome)
is covered effectively by each method, the theoretical maximum
number of sites for different features of the genome was calculated
(see Figure 1 and Table S1) (see Methods for details) along with
their coverage by each method. For MeDIP-seq, the region or
feature was defined as being covered if any part of the region or
feature was covered by, or overlapped with, one or more
sequencing reads with a mapping quality score$10. The coverage
of different genomic features by MeDIP-seq data was consistent
between the two samples (see Table S1), illustrating a high degree
of reproducibility for the technique. The coverage shown for the
HumanMethylation 450K is based on the array design and
reported as the number of regions or features with at least one
probe present on the array mapping to them.
The two techniques showed different extents of coverage with
respect to the calculated genomic features as expected (see
Figure 1). MeDIP-seq showed a high coverage of the majority of
genomic features (approaching 100% for many of them): 87.7% of
CpG sites, 97% of CpG islands and 98% of the CpG island shores
and shelves, 92.4% of RefSeq genes.
The HumanMethylation 450K array coverage was comparable
in the targeted areas in most categories with the exception of CpG
sites, GENCODE genes and regulatory elements. The Human-
Methylation 450K array interrogates a total of 485, 577 CpH sites
which includes 482,421 (or 1.7%) of the 28 million CpG sites
genome-wide [28]. The array targets 94% of the RefSeq gene
collection (based on annotation from ENSEMBL); although this
collection represents a well-annotated set of sequences, it is a very
conservative group and does not describe all known genes in the
human genome. This results in a lower coverage of other (non-
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RefSeq) genes by the HumanMethylation 450K array compared
to whole genome approaches.
In order to describe the genes not included in RefSeq we used
the annotation from the GENCODE consortium (part of the
ENCODE project) which is responsible for the accurate annota-
tion of all evidence-based gene features in the human genome
[37]. Based on the GENCODE annotation, we generated 310,060
unique expressed cluster regions (ECRs) (see Supporting Informa-
tion). Approximately fifty-eight thousands of these ECRs con-
tained additional annotation not present in RefSeq. These 58,047
ECRs contained exons from 25,582 unique ENSEMBL and
HAVANA genes, of which, 7,806 (30.5%) have an official HGNC
identifier (HUGO Gene Nomenclature Committee at the Euro-
pean Bioinformatics Institute, http://www.genenames.org/),
2,981 (11.7%) are linked to an OMIM entry (Online Mendelian
Inheritance in Man, OMIMH, http://omim.org/), and 3,830
(15.0%) have Gene Ontology annotation [38] (see Table S2) and
could include genes that prove to be disease-associated. The ECRs
also contained 17,745 genes with no external annotation and as
such potentially represent novel genes. The HumanMethylation
450K array targets 38% of these unique ECRs in contrast to
MeDIP-seq, which covered over 96% of GENCODE ECRs.
The HumanMethylation 450K array targets 3091 CpW sites
(CpA or CpT) in the human genome. MeDIP-seq targets methyl
cytosine regardless of the sequence context and will target not only
CpG but also all methylated CpH sites (CpA, CpT or CpC) in the
genome (Figure 1 and Table S1). In our study, 80.4%, 81.1% and
82.8% of CpA, CpT and CpC dinucleotides, respectively, were
covered by MeDIP-seq data, although a proportion of this
coverage may be due to their proximity to methylated CpGs.
Comprehensive coverage of other CpH sites may prove to be
biologically important. Methylation at different CpN sites has been
described in pluripotent cells [20,39,40,41], although its biological
significance is currently unknown.
Looking at the repetitive elements in the genome, MeDIP-seq
data provided 96% coverage of transposable elements compared
to less than 2% by the HumanMethylation 450K array. A major
advantage of the immunoprecipitation and sequencing based
methods in comparison to the hybridisation based methods is their
ability to assay the methylation status of CpG dinucleotides in
repeats, which is illustrated by our results. More than 45% of the
human genome is derived from transposable elements and nearly
half of all CpGs fall within repetitive regions of the genome [42].
Aberrant methylation in repetitive DNA was the first epigenetic
alteration shown to play a role in cancer [36,43,44], and there is
an increasing association with the methylation state of repetitive
DNA and disease [36,45,46], which remains an area of very active
research.
In order to determine the concordance in methylation levels
between the two techniques, we first validated both the
HumanMethylation 450K and MeDIP-seq data by comparison
to bisulfite sequencing. Thirty-four CpG islands associated with 41
genes on the X chromosome had been previously selected for
analysis on the basis of their chromosomal location and reported X
chromosome inactivation (XCI) status (see Supporting Informa-
tion) [47]. Genomic DNA from GM01240 and GM01247 was
subjected to clonal bisulfite sequencing of these islands (see
Methods), resulting in between 24 and 94 molecules with sequence
data per CpG island. From the 34 islands, sequence data were
generated for 4386 CpG sites with an average of 65 molecules per
amplicon, giving a very high depth and quality of bisulfite
sequence (average bisulfite conversion efficiency of 99.81%) for the
validation (Table S3). The bisulfite data were analysed with
Figure 1. Coverage by MeDIP-seq and the HumanMethylation 450K BeadChip of different genomic features. The different features are
described along the bottom axis. 100% coverage is defined as covering all of the elements of a particular type in the human genome. Coverage for
MeDIP-seq data (MD-s) (averaged for GM01240 and GM01247) is shown as blue bars and for the HumanMethylation 450K (450K) as red bars. Average
percentages covered for each technique for each group of features are given above the bar chart. For MeDIP-seq the region or feature was defined as
being covered if any part of the region or feature was covered by or overlapped any part of one or more sequencing reads. The coverage for the
MeDIP-seq was consistent between the two samples (see Table S1), illustrating a high degree of reproducibility for the technique. The coverage
shown for the HumanMethylation 450K is reported as the number of features where at least one probe present on the array mapped within the
features under consideration i.e. is based on the array design.
doi:10.1371/journal.pone.0050233.g001
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MethTools [48] (see Methods) and the percentage methylation for
every CpG site assayed calculated.
Out of the 4386 CpG sites for which sequence was generated,
the positions of 326 sites were found to match exactly with CpG
dinucleotides interrogated by probes on the HumanMethylation
450K array. We compared the average-beta values for each of
these probes and the methylation score calculated by the MEDIPS
software package [49] for the corresponding 300 bp window for
the MeDIP-seq data to the methylation levels for the bisulfite data.
Overall there was a strong positive correlation between both the
HumanMethylation 450K and the MeDIP-seq data with the
bisulfite sequencing data (Spearman correlation of 0.75 for the
HumanMethylation 450K vs. bisulfite data, and 0.74 for the
MeDIP-seq vs. bisulfite data, see Table 1), thus validating both
methods. There was also good correlation overall of over 0.6
between the HumanMethylation 450K and MEDIPS data for
these regions on the X chromosome covered by the bisulfite data.
However, in some of the regions the two different methods did
vary in their methylation level estimates (see HCFC1/TMEM187
in Figure 2) resulting in the lower correlation. This may be due to
the fact that bisulfite sequencing and HumanMethylation 450K
data both consist of methylation level estimates for single CpG
dinucleotides whereas for MeDIP-seq, MEDIPS will summarise
the methylation levels of all CpN sites in each 300 bp window.
Having validated the HumanMethylation 450K and MeDIP-
seq data, a similar correlation analysis was done across the
autosomal chromosomes to look at the genome-wide concordance
between the HumanMethylation 450K array and MeDIP-seq
(Table 1). There was a good positive correlation between the two
methods (Spearman correlation of 0.68) for both samples
indicating good agreement between the methods on a genome-
wide level, supporting our observations for the X chromosome.
In order to simplify the comparison between the three different
data sets we tried an alternative approach. The methylation levels
for each individual CpG site assayed by the bisulfite data were
classified as low, medium or high (L/M/H) based on the output
from MethTools (see Supporting Information). The boundaries for
low, medium and high methylation for each probe for the
HumanMethylation 450K array or window for the MEDIPS data
were determined by comparison to the bisulfite sequencing data
(see Supporting Information). All overlapping loci on the X
chromosome from the different methods were then compared
(Table S4). We observed very good agreement between the
different methods (see Figure 2 and Figure S4: 88% of sites were
classified identically between the bisulfite sequencing data and the
HumanMethylation 450K data, and 84% between bisulfite
sequencing data and MeDIP-seq data (Table 2). There was 80%
agreement between the HumanMethylation 450K data and
MeDIP-seq data (see Table 2).
We looked at the regions that showed the highest differences
between the HumanMethylation 450K and MeDIP-seq data and
the clonal bisulfite sequencing data. Considering the Human-
Methylation 450K data, in 40 out of 326 (12%) individual CpG
sites, the methylation level was estimated to be essentially different.
In 28 out of those 40 sites (70%), the estimated 450K methylation
level was lower than the corresponding BS methylation level. This
suggests that in semi- or highly methylated sites, the Human-
Methylation 450K tends to systematically underestimate the
methylation level. Furthermore, in 0.9% of those loci, the
methylation level estimates were directly conflicting (Low vs.
High) and in all those conflicting cases the methylation level was
estimated as ‘‘High’’ in the bisulfite sequencing data and ‘‘Low’’ in
the HumanMethylation 450K data.
A similar analysis was carried out for the MeDIP-seq data; in 16
out of 136 (11.8%) MEDIPS windows which overlapped with the
clonal bisulfite sequencing data, the methylation level was
estimated to be different. In 10 out of those 16 sites (62.5%), the
estimated MEDIPS methylation level was lower than the
corresponding BS-s methylation level. Furthermore, when com-
paring BS-s and MEDIPS there were no regions with directly
conflicting (low vs. high) methylation level estimates.
We also looked at the GC content in the regions demonstrating
the highest differences in methylation level estimates between the
HumanMethylation 450K and MeDIP-seq. The average GC
content for the MEDIPS windows was 47.5%, very similar to
49.5% for the HumanMethylation 450K data. This suggests that
GC content is unlikely to be contributing to these differences.
Using the L/M/H interval-based approach we looked at the
correlation between HumanMethylation 450K data and MeDIP-
seq data over the autosomal chromosomes. The two methods
showed a correlation above 0.6 (Table 2) with 63% of loci
classified identically for GM01240 and 61% for GM01247 loci
classified identically. Only 28,796 (6%) of loci in GM01240 and
16,715 (4%) of loci in GM01247 had directly conflicting (low vs.
high) methylation estimates. Without additional experimental
validation it is not possible to say definitively which technology is
the more correct estimate of methylation levels in the regions of
conflict. However, looking at those loci that are in direct conflict,
and averaging over the two samples, 5.5% of loci that are
estimated as ‘‘Low’’ by MEDIPS are estimated as ‘‘High’’ by the
450K array and 94.5% of loci estimated as ‘‘High’’ by MEDIPS
are estimated ‘‘Low’’ by the 450K array. This suggests that either
MEDIPS systematically overestimates the methylation level in
regions that have no or low methylation levels or that 450K
systematically underestimates methylation levels in regions that are
highly methylated.
Both the HumanMethylation 450K array and MeDIP-seq have
been previously shown to be capable of detecting differential
methylation in the human genome [24,29,30,35,36]. The total
number of differentially methylated loci detected by the Human-
Methylation 450K array will be less than the number detected by
MeDIP-seq because of the limitations of the targeted design versus
the whole genome approach.
To determine differential methylation using the HumanMethy-
lation 450K array, we used a similar approach to that of Sandoval
et al., (2011) and Dedeurwaerder et al., (2011) (see Methods). Using
our criteria, we found 8070 methylation variable positions (MVPs)
[50] between samples GM01240 and GM01247 (excluding the Y
chromosome), of which 5296 were located on autosomal
chromosomes.
Differential methylation analysis was carried out on the MeDIP-
seq data using the MEDIPS program (see Methods). Using our
selection criteria, we detected 15,709 significant DMRs (excluding
the Y chromosome) between samples GM01240 and GM01247, of
which, 8244 were autosomal in origin. A large number of the
autosomal DMRs (7991) overlapped partially with different
repetitive elements of the genome. Nearly half of the CpGs in
the human genome are known to be located in repetitive regions
[42], which is supported by our results. It is thought that
methylation of repetitive elements in the human genome is
biologically relevant and is a possible mechanism for control of
active retrotransposons [51].
Interestingly, 5873 (71%) of the autosomal DMRs detected by
MEDIPS were hypermethylated in the male sample (GM01247)
and 2371 (29%) were hypermethylated in the female sample
(GM01240). In the HumanMethylation 450K data, 58% of MVPs
were hypermethylated in the male sample and 42% in the female
Comparison of MeDIP-Seq to HumanMethylation 450K
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sample. These data support the idea that there is a wealth of non-
sex chromosome genes that are differentially methylated (and
therefore potentially also differentially regulated) between males
and females [52].
To look at the concordance of the differential methylation
detected by the two methods, we compared the MVPs found with
HumanMethylation 450K array to the DMRs found with the
MeDIP-seq data (see Supporting Information). Out of the total of
8070 MVPs detected with the HumanMethylation 450K platform,
Figure 2. Comparison of methylation level estimates for the bisulfite sequencing, HumanMethylation 450K and MeDIP-seq data.
Data are shown for the 28 islands (associated with 36 genes) containing CpG sites that overlapped with those interrogated by HumanMethylation
450K array for sample GM01240. Evolutionary strata information is shown to the right of the ideogram of the human X chromosome [66]: the blue
line represents the S3 stratum; the purple line represents the S2 stratum and the red line the S1 stratum. Both names are given for genes sharing a
CpG island separated by ‘‘/’’. Methylation level estimates for each of the techniques are shown to the right of the gene names in light green (low),
green (medium), and dark green (high). Examples of four genes are shown in more detail on the right of the figure. The gene names are highlighted
in colour at the top of each panel and in a corresponding colour on the gene list. Data for the bisulfite sequencing (BS-s), HumanMethylation 450K
(450K) and MeDIP-seq (MD-s) are shown at the top, center and bottom of each panel, respectively. The genes shown give examples where the three
techniques agree in methylation level: low level methylation in the gene ZFX, medium level methylation in the PRPS2 gene, and a high level of
methylation in the ACRC gene. Data are also given for the HCFC1/TMEM187 genes, for which different methods show inconsistency in the classified
methylation levels. See Figure S4 for data for sample GM01247.
doi:10.1371/journal.pone.0050233.g002
Table 1. Concordance of the HumanMethylation 450K (450K) and MeDIP-seq (MD-s) data with bisulfite sequencing (BS-s) data.
Dataset Concordance
Regions with bisulfite data (X chromosome) BS-s – 450K 0.75
BS-s – MD-s 0.74
450K – MD-s 0.62
Whole genome data (autosomal chromosomes only) 450K – MD-s (GM01240) 0.68
450K – MD-s (GM01247) 0.68
The top part of the table gives the concordance of the average beta-values for the 326 probes on the X chromosome from the HumanMethylation 450K (450K) and the
methylation score calculated by the MEDIPS software for the MeDIP-seq data (MD-s) to the methylation levels for the bisulfite data (BS-s) from MethTools. The second
half of the table contains the concordance for a similar analysis for the HumanMethylation 450K and MeDIP-seq data for all autosomal chromosomes.
doi:10.1371/journal.pone.0050233.t001
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2208 overlapped with 509 significant DMRs found with MeDIP-
seq (Figure 3A). The overall concordance for the overlapping
MVPs/DMRs was good: in 97.4% of differentially methylated loci
found by both methods the direction of the differential methyl-
ation agreed. Figure 3B shows the location with respect to different
genomic features of the DMRs detected by both techniques.
5203 autosomal only MVPs were detected by the Human-
Methylation 450K array only, i.e. none of them overlapped with a
significant DMR found using MEDIPS. On inspection, 4911
(94%) of these were covered by MeDIP-seq reads and had been
detected by the MEDIPS DMR analysis but had been excluded as
lower confidence DMRs. Conversely, 8181 autosomal DMRs
were detected by MeDIP-seq only. Of these, 1030 (12.6%), had
one or more HumanMethylation 450K probes that overlapped
with them but had been excluded as being not significant MVPs.
Figures 3C and 3D illustrate the genomic features covered by the
differentially methylated loci detected by MeDIP-seq or the
HumanMethylation 450K respectively. The exact number of
DMRs or MVPs found in different genomic features is also given.
It is important to note that many of the genomic elements overlap
with each other. For example, for MD-s, the number of significant
DMRs that overlap with LINE elements is 4639 as shown.
However, the number of DMRs that overlap with LINE elements
which do not overlap with any other genomic feature is 2767.
Additionally, in the case of the DMRs found by MD-s, many of
the longer DMRs span several different genomic features.
Our results show that for methylation level determination both
the Infinium HumanMethylation450 BeadChipH and MeDIP-seq
are reliable and correlate well with each other. Both methods can
be used successfully to determine differentially methylated loci in
RefSeq genes, CpG islands, shores and shelves. MeDIP-seq
however interrogates more regions of the human genome,
including non-RefSeq genes and repetitive elements, allowing
the detection of nearly twice as many differentially methylated
regions.
Discussion
One of the important driving forces in the study of epigenetics is
the impact of epigenetics in disease. There are still relatively few
common diseases that have been explained fully by conventional
single nucleotide polymorphism (SNP), indel (short insertions/
deletions) and copy-number variant (CNV) analyses [5]. Some of
the remainder could potentially be explained by alterations in
DNA methylation patterns. It has also been suggested that
environmental influences on epigenetic modifications could be
an important factor in disease risk [3].
The study of epigenetics is expanding rapidly with several large-
scale projects underway analysing large collections of samples from
different tissues (IHEC: http://www.ihec-epigenomes.org/index.
html; NIH Roadmap Epigenomics Mapping Consortium: http://
www.roadmapepigenomics.org; BLUEPRINT, http://www.
blueprint-epigenome.eu). Growth in this field has driven techno-
logical developments to increase the capacity and efficiency of the
methods available for studying the methylome. Selection of the
appropriate method is imperative and, with increasing impor-
tance, should enable comparison of data produced by the large
international collaborative efforts currently underway. With this in
mind, our study presents a comparison between the targeted
approach of the Infinium HumanMethylation450 BeadChipH and
MeDIP-seq, an immunoprecipitation and sequencing- based
method covering the whole genome.
Our results show that both methods are capable of providing
accurate and robust results. One of the fundamental differences
between the two is the coverage of the genome and methylome
provided. MeDIP-seq can detect methylation at any methylated
CpN site in the genome and is therefore theoretically capable of
100% coverage of the methylome. Along with other whole
genome-based techniques, this makes MeDIP-seq very useful for
hypothesis free discovery of methylation states and changes
therein. As with other sequencing based techniques, there are
some limitations due to the challenge of mapping sequencing reads
accurately within highly repetitive and complex regions of the
genome (and hence the methylome). Nevertheless, use of MeDIP-
seq and other genome-wide methods will inevitably lead to a more
complete picture of the methylome than the targeted approach. In
addition, the ability to detect regions of non-CpG differential
methylation may be biologically relevant for the assessment of the
effect of methylation in pluripotent cell types [41]. There are a
significant number of genes and other genomic features that are
not targeted by the HumanMethylation 450K array that are
potentially of functional significance. Hence the HumanMethyla-
tion 450K is not as suitable for hypothesis free discovery or for
detecting methylation outside of RefSeq genes and other known
features.
A major advantage of sequencing-based methods such as
MeDIP-seq is the ability to interrogate repetitive elements (nearly
50% of the CpGs in the genome fall in repetitive regions). These
CpGs are not easily assayed by array-based methods due to the
problems of cross-hybridisation, a limitation of array-based
Table 2. Concordance of the HumanMethylation 450K (450K) and MeDIP-seq (MD-s) data with bisulfite sequencing (BS-s) data
using an interval-based approach.
Dataset Concordance
Regions with bisulfite data (X chromosome) BS-s – 450K 0.88
BS-s – MD-s 0.84
450K – MD-s 0.80
Whole genome data (autosomal chromosomes only) 450K – MD-s (GM01240) 0.62
450K – MD-s (GM01247) 0.61
The methylation levels for each individual CpG site assayed by the bisulfite data (BS-s) were classified as low, medium or high based on the output from MethTools. The
boundaries for low, medium and high methylation intervals for each probe for the HumanMethylation 450K array (450K) and corresponding window for the MEDIPS
data were determined by comparison to the bisulfite sequencing data. In the top part of the table the concordance between these intervals was calculated for all
overlapping loci from the different methods for the regions covered by the bisulfite data. The second half of the table contains the concordance for a similar analysis for
all autosomal chromosomes for the MeDIP-seq (MD-s) and HumanMethylation 450K data.
doi:10.1371/journal.pone.0050233.t002
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techniques and will have implications for the study of some
diseases where methylation in these regions is an important factor.
MeDIP-seq is a relatively low resolution technique that can
detect methylated regions of approximately 150–200 bp rather
than the individual single nucleotide sites detected by the
HumanMethylation 450K. Although the highest possible resolu-
tion of a single base-pair is desirable, the methylation state of
neighbouring CpG sites has been shown to be highly correlated
over distances as great as 1000 bp [53,54]. Depending on the
research question it may not be absolutely necessary to have single
base pair resolution and the resolution provided by MeDIP-seq
may be sufficient.
The analysis of methylation data requires an understanding of
the differences in resolution between methods used. MeDIP-seq
provides regional methylation information, likely to arise from
several MVPs. In the HumanMethylation 450K array, single CpG
sites are assayed providing exact positional information. These
sites are likely to have methylation levels indicative of the regional
methylation surrounding the MVP given that methylation levels
have been shown to be correlated within regions of up to 1 kb. It is
possible to perform a more regional analysis using single site based
array data using custom arrays designed to cover multiple
consecutive clustered MVPs. This approach, CHARM, (Compre-
hensive High-throughput Arrays for Relative Methylation) [55]
was developed to allow genome weighted smoothing and more
confident calling of DMR from array data [55]. Application of the
CHARM method may be possible with future higher density
designs of the Infinium array enabling clustering of MVPs.
CHARM arrays have recently been technologically extended to
encompass significantly larger numbers of CpGs up to 5.2 million
CpG sites [56] and although this would not cover all 28 million
CpGs in the human genome, this method may offer a suitable
alternative that has some of the benefits of MeDIP-seq with the
flexibility and cost efficiency of an array.
Our results also show that both techniques are capable of
detecting differential methylation. As expected, the number of
Figure 3. Differentially methylated loci detected by the HumanMethylation 450K array (450K) and MeDIP-seq (MD-s). (A) The
numbers of methylation variable positions (MVPs) detected the by the 450K array (autosomal and X) are given in the red circle, and the number of
differentially methylated regions (DMRs) detected with MD-s in the blue circle. The number of differentially methylated loci detected by both
methods is given in the intersection of the two circles. Any DMR detected by MD-s within this intersection contained one or more significant MVP(s)
detected by the 450K array. (B) Location with respect to different genomic features of the differentially methylated regions detected by both
methods (see key to the bottom right of the figure for the genomic feature represented by each colour). (C) Exact number of and location with
respect to different genomic features of the DMRs detected by MD-s only. (D) Exact number of and location with respect to different genomic
features of the MVPs detected by 450K only. It is important to note that many of the genomic elements overlap with each other. Additionally, in the
case of the DMRs found by MD-s, many of the longer DMRs span several different genomic features.
doi:10.1371/journal.pone.0050233.g003
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differentially methylated autosomal loci detected by the targeted
method (HumanMethylation 450K) was smaller than with the
hypothesis-free approach of MeDIP-seq (5296 vs. 8244 respec-
tively). It is important to note that the HumanMethylation 450K
array will detect differentially methylated sites (not regions)
between compared samples. Conversely, with MeDIP-seq it is
only possible to detect differentially methylated regions and not
possible to detect single differentially methylated sites, requiring
additional analysis to determine the state of the individual CpN
sites involved.
The HumanMethylation 450K has been designed to facilitate
the processing of large numbers of samples in a high-throughput
and cost-effective manner. MeDIP-seq is commonly thought to be
more costly and less amenable to large sample numbers but can be
successfully automated [57]. Taiwo et al., reported that 60 million
high-quality reads would cover up to 70% of all CpGs at a
minimum of 16and 30% of all CpGs at a minimum of 106 [58].
Typically 60–80% of CpGs in the genome are methylated. With
this is mind Taiwo et al., suggest that a typical MeDIP-seq
experiment would interrogate most methylated CpGs at 16 [58].
Li et al., (2010) estimated that 3 Gb of data are sufficient to study
the methylome using MeDIP-seq [16]. This estimate is in broad
agreement with the number of reads required as suggested by
Taiwo et al., [58]. The amount of sequence data generated in our
study is therefore more than the recommended minimum amount
required to give good coverage of the methylome. Based on these
figures MeDIP-seq samples could be indexed allowing multiplex-
ing of up to 6 samples per Illumina HiSeq lane at the current level
of data production. This has a positive effect on cost such that
MeDIP-seq becomes at least 186 more cost effective per CpG
dinucleotide than the HumanMethylation 450K. As a conse-
quence sequencing-based enrichment methods should not neces-
sarily be thought to be prohibitively expensive for looking at the
methylome.
Looking at our results, the dynamic range of HumanMethyla-
tion 450K and MeDIP-seq data appears to be less than that of
bisulfite sequencing. For MeDIP-seq, this is partially due to the
software used to analyse the data, MEDIPS. In any one window,
MEDIPS will average out or ‘‘smooth’’ peaks of methylation
resulting in a smaller dynamic range. This may give the false
impression that MeDIP-seq is less efficient at capturing highly
methylated regions of the genome. However, this is an artefact of
the data analysis. Analysis of MeDIP-seq data remains problem-
atic despite there being several methods available [24,59,60].
The evolution and development of second-generation sequenc-
ing has revolutionised how we study DNA methylation. The once
impractical, costly whole genome experiment can now be
performed in a more cost- and time- efficient manner using
methods such as MeDIP-seq (and others) that reduce the amount
of sequencing needed and increase the coverage of data generated
for methylated regions of the genome. For small numbers of
samples or smaller genomes, it is possible to sequence an entire
bisulfite-converted genome [18,19,20,54]. However, despite the
reduction in costs and increase in sequencing yields, price and
throughput still remains a barrier to researchers wishing to carry
out large-scale studies with a sufficient depth of coverage. The
array-based HumanMethylation 450K provides an accessible
alternative capable of producing data from large numbers of
samples and allowing cross sample comparisons relatively easily
but is limited by its targeted design. Although the Infinium
HumanMethylation450 BeadChipH is an improvement on its
predecessor (the Infinium HumanMethylation27 Bead-ChipH),
our study has shown that it may not be the most comprehensive
tool for studying the methylome but will deliver affordable robust
and standardised data in those regions that it targets allowing
easier comparison between different studies. Additionally it is
relatively simple to integrate the HumanMethylation 450K data
with genotyping data from genome-wide association studies and
gene expression data to look at the relationship between genotype,
methylation and expression. However, analysis of HumanMethy-
lation 450K data has proved to be challenging with significant
issues around QC and data normalisation. New methods for
analysis are continually being developed and published, each of
which has its merits. Whilst great progress has been made it is still
not clear which of the available methods is the most suitable [61].
In summary, MeDIP-seq would be the method of choice when
the impact of, and/or genomic location of, methylation in the
samples under study is unknown or is likely to be outside of RefSeq
genes, for example in repetitive regions of the genome. MeDIP-seq
is automatable and as sequencing costs continue to fall, and DNA
requirements for MeDIP-seq decrease, it is becoming more
suitable for larger sample sets and a wider range of samples
including precious clinical samples where DNA may be limited. It
is also capable of analysing both 5mC and 5hmC in contrast to the
HumanMethylation 450K. The HumanMethylation 450K Bead-
ChipH is currently more amenable for high-throughput experi-
ments with large number of samples. It would be a suitable
method of choice if the methylation or change of methylation state
in question is thought to be in well-characterised genes. It would
also be the method of choice when comparing results across studies
and integrating methylome data with, for example, array-based
expression data. The coverage of RefSeq genes is very good for the
HumanMethylation 450K BeadChipH, however, coverage of
other regions of the genome is more limited, and, limited to the
study of 5mC.
Currently no single method provides what is ultimately required
for the study of the methylome – a cost-effective, unbiased method
requiring a small amount of input sample and which will allow
processing of large numbers of samples and detect (and distinguish
between) all methylation marks including 5mC and 5hmC at
single nucleotide resolution in one experiment. Whilst we are
moving towards being able to detect DNA methylation and other
DNA modifications directly using nanopores [62] and single-
molecule, real-time sequencing methods [63,64] there are still
significant challenges to address before these methods are a
practical choice for high throughput methylation projects. We will
therefore continue to need to make choices about the best
available methods for our investigations whilst considering the
scope and detail of the biology we aim to unravel.
Methods
Ethics statement
This study has been approved by the ethics committee of the
Wellcome Trust Sanger Institute (WTSI). This study only used
extracted DNA from cell-lines, which falls outside of the UK
Human Tissue Act.
Genomic DNA samples and DNA extraction
The two cell lines used in this study, GM01240 (XX) and
GM01247 (XY), (a sibling pair of European descent), were sourced
from the NIGMS Human Genetic Cell Repository at the Coriell
Institute for Medical Research. Genomic DNA (gDNA) was
extracted from cell pellets using a DNeasy Blood and Tissue kit
(Qiagen) according to the manufacturer’s protocol including
treatment with RNaseA and Proteinase K.
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Calculation of number of sites of different features in the
genome
The coordinates for CpG islands, regulatory elements, RefSeq
genes (and other related elements) and human repetitive elements
were downloaded from the ENSEMBL database (v63). CpG island
shores were calculated at 2 kb either side of an island and CpG
shelves as the 2 kb extending from the shores. The number of
CpG shelves is fewer than the number of CpG shores because if
two CpG islands are less than 4 kb apart they will be separated by
one or two shores but no shelves. Coordinates for GENCODE
ECRs were calculated from the GENCODE database (v8) by
collapsing all overlapping GENCODE genes into expressed cluster
regions (see Supporting Information). Coordinates for all CpN
sites were extracted from the GRCh37 1000 Genomes reference
genome (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/
reference/human_g1k_v37.fasta.gz).
Methylated DNA immunoprecipitation sequencing
(MeDIP-seq)
Five micrograms of gDNA were randomly sheared to a median
fragment size of 200 bp using a Covaris S220. Illumina Paired
End libraries were prepared as described in the manufacturer’s
protocol except for the replacement of the gel purification and size
selection step in the final stage with purification using Agencourt
AMPure XP SPRI beads (according to the supplier’s protocol).
The resulting libraries were assessed for quantity and size using an
Agilent 2100 Bioanalyser and DNA 1000 assay.
Methylated DNA immunoprecipitation was performed using
the Methylated-DNA IP kit (Zymo Research) using a 1:10 ratio of
DNA to antibody. Before precipitation 480 ng of the Illumina
Paired End library (Input DNA) were diluted in DNA denaturing
buffer to a final volume of 60 ml and denatured at 98uC for
5 minutes. 5 ml (40 ng) were retained for use as an input control
and purified using a MinElute PCR Purification Kit (Qiagen) with
a final elution into 15 ml elution buffer (EB). 50 ml (400 ng) of
denatured sample were used in the immunoprecipitation (IP)
reaction which was incubated for 1 hr at 37uC @ 700 rpm,
purified according to the manufacturers’ instructions and eluted in
15 ml DNA elution buffer. MeDIP efficiency was assessed by
performing comparative Ct quantitative PCR using the IP and
input samples as template, Power SYBR green PCR master mix
(Applied Biosystems) and primers supplied by Diagenode (see
Supporting Information for primer details). qPCR was performed
using a StepOnePlus Real-Time PCR system (Applied Biosystems)
with the following cycling conditions: 95uC for 10 mins, followed
by 40 cycles of 95uC for 15 sec; 60uC for 1 min and concluded
with melt curve analysis. MeDIP efficiency was calculated using
the manufacturer’s formula (see Supporting Information for
details). MeDIP percentage recovery and percentage specificity
results for GM01240 and GM01247 can be seen in Table S6.
A library enrichment step was performed using 10 cycles of
PCR according to the Illumina Paired End Sample Prep protocol
and the resulting libraries assessed for quantity and size using the
Agilent 2100 Bioanalyser and DNA 1000 assay. Each MeDIP-seq
library was sequenced as paired-end to saturation on one lane of
an Illumina HiSeq 2000 using 75 cycles (see Figure S2). The raw
sequencing reads are available through the European Genome-
Phenome Archive (http://www.ebi.ac.uk/ega, accession to be
supplied).
Sequence reads were aligned to the human reference genome
(1000 Genomes version of GRCh37) using Burrows–Wheeler
alignment (BWA). Duplicates were mapped with Picard MarkDu-
plicate tool (see Table S5 for sequencing statistics for each sample).
High quality sequence data (reads with a mapping quality score of
$10) were analysed using the MEDIPS software package [49] to
estimate methylation levels. Estimates were calculated for all
consecutive 300 bp windows across the genome for each sample.
Differential methylation analysis was carried out using MEDIPS in
500 bp windows excluding regions with no read coverage in both
samples. Genomic regions with at least three consecutive windows
that were statistically significantly differentially methylated be-
tween compared samples were considered to be differentially
methylated regions (DMRs).
Genome-wide methylation profiling using the Illumina
Infinium HumanMethylation450 BeadChip
Bisulfite conversion of 1 mg of the DNA sample was performed
using the EZ-96 DNA Methylation Kit (Zymo Research)
according to the manufacturer’s protocol. 5 ml of the bisulfite
converted DNA were used for genome-wide methylation profiling
using the Illumina Infinium HumanMethylation450 BeadChip
according to manufacturer’s protocol. Post-hybridisation and
washing, the BeadChips were scanned using the Illumina HiScan
SQ scanner. The efficiency of the bisulfite conversion was checked
according to the manufacturer’s protocol.
Raw image data were imported into the GenomeStudio v2010.3
Methylation module (version 1.8.2. using the human genome
reference version 37) which was used to extract the fluorescent
signal intensities and normalise the data. Briefly, background
signal intensity was subtracted from the raw signal intensity values
and data were normalised with respect to the Illumina internal
control probes. The methylation level for each probe was
calculated as an average beta-value scaled from 0 to 1 (AVG_Beta)
representing the ratio of the intensity of the methylated beads to
the combined locus intensity. Results of this analysis were exported
from GenomeStudio as standard report files and further analysed
with custom scripts.
To detect methylation variable positions (MVPs) we used a
similar approach to that described in Sandoval et al., (2011) and
Deduerwaerder et al., (2011). Methylation levels, estimated as
average beta values, for both samples, were compared in a probe-
wise manner and any locus for which the corresponding
methylation level estimates (AVG_Beta) differed by at least 2-fold
and by 0.2 or more was considered to be differentially methylated.
We added the additional requirement of an absolute difference of
0.2 in AVG_Beta values to avoid the situation where CpG sites with
methylation level estimates of 0.01 in one sample and 0.02 in the
other sample would be called as differentially methylated despite
the $2-fold difference criteria being fulfilled.
Clonal bisulfite sequencing
Genomic DNA from GM01247 and GM01240 was prepared
for bisulfite treatment by fragmentation by restriction digestion.
Digests were performed using 18–25 mg DNA with 100 U Hind
III in 16NEB2 buffer and incubated at 37uC overnight. Digested
DNA was purified using phenol: chloroform: isoamyl alcohol
extraction followed by an ethanol/sodium acetate precipitation
step. 1.2 mg of digested DNA were subjected to bisulfite conversion
using the EZ DNA Methylation KitTM (Zymo Research). 25–
50 ng of bisulfite converted genomic DNA were used as a template
for Hot-start PCR using primers designed to amplify selectively the
bisulfite converted DNA across targeted CpG islands (see Table S3
for primer sequences and Supporting Information for details of
primer design and validation and amplification conditions).
PCR products were purified prior to cloning using a MinElute
PCR Purification Kit (Qiagen), and then ligated into the pGEMH-
T Easy Vector (Promega). Transformations were performed using
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One ShotH Mach1TM T1 Phage-Resistant Chemically Competent
E. coli (Invitrogen). Cells were plated onto selective agar containing
Ampicillin and X-gal and incubated at 37uC overnight. A small
number of colonies were checked by colony PCR using standard
protocols. 96 colonies from each ligation (amplicon) were
subjected to an automated 96-well plasmid prep using standard
protocols. The resulting DNA was sequenced using M13 forward
and reverse primers and ABI Prism Big Dye Terminator v3.1
chemistry. Reactions were run on ABI 3730 sequencers with the
ABI base-calling algorithm KB Basecaller.
Sequence data were assembled into a GAP database [65]
(version 4), and manually curated to remove poor quality data
from the assembly. For each amplicon the remaining high quality
data were exported in FASTA format and aligned to in silico
bisulfite converted reference sequence and unconverted genomic
sequence using the ClustalW 1.8 (http://searchlauncher.bcm.tmc.
edu/multi-align/Options/clustalw.html). Text files were generat-
ed containing the aligned and original parent sequences from each
amplicon and submitted to MethTools to calculate the percentage
of methylated molecules for each CpG assayed [48] (http://
genome.imb-jena.de/methtools/).
Supporting Information
Figure S1 Outline of the comparison of MeDIP-seq to the
HumanMethylation 450K array. The two methods were com-
pared on DNA from two cell lines; GM01240 (XX) and GM01247
(XY), a sibling pair of European descent (see Methods), generating
a total of four methylation profiles for analysis. Two different
methods of analysis were tested per technique: For the
HumanMethylation 450K we tested both GenomeStudio in
combination with custom-written scripts as well as the IMA
package [67]. For the analysis of the MeDIP-seq data we tested
both MEDIPS and Batman. In addition, a subset of data from
each methylation profile was validated by comparison to clonal
bisulfite sequencing data from 34 CpG islands on the human X
chromosome which was used as the gold standard.
(TIF)
Figure S2 Saturation analysis of MeDIP-seq data for samples
GM01240 (A) and GM01247 (B). Results from the MeDIP-seq
satuaration analysis calculated by part of the MEDIPS package
that checks if the number of input regions (MeDIP-seq sequencing
reads) is sufficient to generate a saturated and reproducible
methylation profile for the analysed sample(s). Note that for both
samples, lines depicting actual saturation and estimated saturation
overlap to a great extent.
(TIF)
Figure S3 Sequencing depth and CpG coverage. The percent-
age of genomic CpG sites covered at different depths of sequence
(fold coverage) is shown for GM01240 (240 M reads, 18 Gb of
sequence ) in dark blue; for GM01247 (234 M reads, 17.6 Gb ) in
green; for GM01240 (120 M reads, 9 Gb ) in blue; for GM01240 (
60 M reads, 4.5 Gb) in light blue; for Sample#1 (82 M reads,
6.3 Gb ) in yellow; for Sample#2 ( 74 M reads, 5.7 Gb ) in red. It
is important to note that Sample#1 and Sample#2 (unrelated to
this study but processed in the same way) were both sequenced on
one lane of an Illumina GAII resulting in a lower sequencing yield
compared to GM01240 and GM01247 which were both
sequenced on one lane of an Illumina HiSeq 2000. The data for
the 120 M and 60 M reads graphs for GM01240 were calculated
from the 240 M dataset by taking a subset of the reads equivalent
to half (1/2) and a quarter (1/4) of the original dataset. All
experimental datasets were sequenced to saturation according to
the MEDIPS saturation analysis (data for GM01240 and
GM01247 are shown on Figure S2).
(TIF)
Figure S4 Comparison of methylation level estimates for the
bisulfite sequencing (BS-s), HumanMethylation 450K (450K) and
MeDIP-seq (MD-s) data. Data are shown for the 28 islands
(associated with 36 genes) containing CpG sites that overlapped
with those interrogated by HumanMethylation 450K array for
sample GM01247. Evolutionary strata information is shown to the
right of the ideogram of the human X chromosome [66]: the blue
line represents the S3 stratum; the purple line represents the S2
stratum and the red line the S1 stratum. Both names are given for
genes sharing a CpG island separated by ‘‘/’’. Methylation level
estimates for each of the techniques are shown to the right of the
gene names in light green (low), green (medium), and dark green
(high).
(TIF)
Table S1 Coverage by MeDIP-seq and the HumanMethylation
450K BeadChip of different genomic features. The theoretical
maximum number of sites for different features of the genome
(Sites or features in the genome) was calculated as follows: The
coordinates for CpG islands, regulatory elements, RefSeq genes
(and other related elements) and human repetitive elements were
downloaded from the ENSEMBL database (v63). CpG island
shores were calculated at 2 kb either side of an island and CpG
shelves as the 2 kb extending from the shores. The number of
CpG shelves is fewer than the number of CpG shores because if
two CpG islands are less than 4 kb apart they will be separated by
one or two shores but no shelves. Coordinates for GENCODE
ECRs were calculated from the GENCODE database (v8) by
collapsing all overlapping GENCODE genes into expressed cluster
regions (see Supporting Information). Coordinates for all CpN
sites were extracted from the GRCh37 1000 Genomes reference
genome (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/
reference/human_g1k_v37.fasta.gz). The coverage shown for the
HumanMethylation 450K (Sites covered by design) is based on the
array design and reported as the number of regions or features
with at least one probe present on the array mapping to them. The
following column gives the percentage of the theoretical maximum
number of sites covered for each feature by the HumanMethyla-
tion 450K. For MeDIP-seq, the region or feature was defined as
being covered if any part of the region or feature was covered by
or overlapped with one or more sequencing reads with a mapping
quality score $10. The number of sites covered for each sample
(GM01240 (XX) or GM01247 (XY)) is given (Sites covered by $1
reads) as well as the percentage of the theoretical maximum
number of sites covered for each feature (Percentage of genomic
sites covered).
(DOCX)
Table S2 Unique ENSEMBL and HAVANA genes with
associated annotation. Based on GENCODE annotation
310,060 unique expressed cluster regions (ECRs) were generated
(see Supporting Information). Approximately fifty-eight thousands
of these ECRs contained additional annotation not present in
RefSeq. These 58,047 ECRs contained exons from 25,582 unique
ENSEMBL and HAVANA genes (column A for the ENSEMBL
ID). Any external ID is given in column B. 7,806 of the ECRs
(30.5%) have an official HGNC identifier (HUGO Gene
Nomenclature Committee at the European Bioinformatics Insti-
tute, http://www.genenames.org/) (column C), 2,981 (11.7%) are
linked to an OMIM entry (Online Mendelian Inheritance in Man,
OMIMH, http://omim.org/) (column D), and 3,830 (15.0%) have
Gene Ontology (GO) annotation (column E). The ECRs also
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contained 17,745 genes with no external annotation and as such
potentially represent novel genes.
(XLS)
Table S3 Summary of clonal bisulfite sequencing data from 81
data sets encompassing 34 CpG islands on the human X
chromosome. This table summarises the clonal bisulfite sequenc-
ing data for the 81 data sets amplifying the 34 CpG islands
selected on the human X chromosome for analysis. For each
amplicon the table gives the evolutionary stratum within which the
CpG island being assayed lies, the official HGNC unique gene
symbol for the gene or genes associated with the island and a
description of the gene itself and its reported X chromosome
inactivation status as described in reference 45. Data are given for
the length of the CpG island in bp. Amplicon length, coordinates
and the sequences of the primers used to amplify each amplicon
are given. Counts are given for the number of CpG dinucleotides
and CpH (CpA/CpT/CpC) dinucleotides in each amplicon. The
number of sequencing reads analysed per amplicon is recorded
alongwith the number of individual molecules analysed. The
average number of molecules analysed per region is given as 65.
The total number of cytosines analysed within the context of a
CpG dinucleotide is calculated (the number of CpGs in the
amplicon6the number of molecules analysed). The total number
of bisulfite converted cytosines (in the context of either CpA, CpT
or CpC) and the number of unconverted cytosines are given. The
percentage of unconverted cytosines (in a CpA, CpT or CpC
context) is calculated. The bisulfite efficiency is expressed as a
percentage. The average bisulfite conversion efficiency across all
81 data sets is 99.81%.
(XLS)
Table S4 Comparison of methylation levels between bisulfite
sequencing, HumanMethylation 450K and MeDIP-seq data for
GM01240 and GM01247 using an interval-based approach. The
HGNC unique gene symbol for the gene associated with the CpG
island being assayed is given. Two gene names separated by ‘‘/’’
indicate two genes share the island. ‘‘XY only’’ indicates that there
are data for sample GM01247 only. ‘‘XX’’ only indicates that
there are data for sample GM01240 only. The coordinates on the
X chromosome (GRCh37) for each individual CpG analysed by
bisulfite sequencing with the percentage methylation determined
by MethTools analysis of the bisulfite sequencing data are given.
For the bisulfite sequencing, the methylation levels for each
individual CpG site assayed were classified as low, medium or high
based on the output from MethTools with low, medium or high
defined as: low (L), methylation level less than 20%; medium (M),
methylation level greater than or equal to 20% and less than 70%)
and high (H), methylation level greater than or equal to 70%. The
bisulfite sequencing data were considered to be the gold standard.
The exact values used for the boundaries for the HumanMethyla-
tion 450K and MEDIPs data were found iteratively by treating the
bisulfite sequencing estimated methylation level as the ‘‘true’’
methylation level and comparing all possible combinations of
boundaries programmatically to maximise the number of correctly
classified overlapping CpG sites and minimise the number of
incorrectly classified overlapping CpG sites between the two
datasets. For the HumanMethylation 450K methylation levels
were defined as low (L), average-beta value of less than 0.21;
medium (M), average-beta value of greater than or equal to 0.21
and less than 0.57, and high (H), average-beta value of greater
than or equal to 0.57. For MEDIPS, methylation levels were
classified as low, medium or high defined as low (L), MEDIPS
score of less than 280; medium (M), MEDIPS score of greater than
or equal to 280 and less than 410, and high (H), MEDIPS score of
greater than or equal to 410The coordinate on the X chromosome
(GRCh37) and name (supplied by Illumina) of the individual
probe from the HumanMethylation450 array used in the analysis
are given. The average beta-value of each probe (scaled from 0 to
1) as calculated by Genome Studio represents the methylation
level for each probe from the HumanMethylation 450K. The
coordinates on the X chromosome (GRCh37) of the window of
MeDIP-seq data analysed by MEDIPS are given, with the
MEDIPS score as a measure of the methylation level. The
coordinate on the X chromosome (GRCh37) and name (supplied
by Illumina) of the individual probe from the HumanMethyla-
tion450 array used in the analysis are given. The average beta-
value of each probe (scaled from 0 to 1) as calculated by Genome
Studio represents the methylation level for each probe from the
HumanMethylation 450K. The coordinates on the X chromo-
some (GRCh37) of the window of MeDIP-seq data analysed by
MEDIPS are given, with the MEDIPS score as a measure of the
methylation level.
(XLSX)
Table S5 Sequencing statistics for MeDIP-seq data for
GM01240 and GM01247. A summary of sequencing statistics
for MeDIP-seq data for GM01240 and GM01247. Each MeDIP-
seq library was sequenced as paired-end to saturation on one lane
of an Illumina HiSeq 2000 using 75 cycles. The total number of
reads post image analysis and QC are given generated for each
sample followed by the number of passed reads are given. The
percentage of GC found in the reads is reported. The total number
of bases sequenced and the percentages of high quality bases are
calculated. Sequence reads were aligned to the human reference
genome (1000 Genomes version of GRCh37) using Burrows–
Wheeler alignment (BWA). The raw number of mapped reads is
given as well as the number of reads mapping to the reference
genome. Duplicates were mapped with Picard MarkDuplicate
tool.
(XLSX)
Table S6 MeDIP percentage recovery and percentage specificity
for GM01240 and GM01247 based on Comparative Ct qPCR
data. The efficiency of the immunoprecipitation in the MeDIP was
assessed by performing comparative Ct quantitative PCR using
the IP and input samples as template. The primer pairs used for
the qPCR for the human TSH2B and GAPDH control genes were
supplied by Diagenode. The human TSH2B gene is known to be
highly methylated in all somatic cells. The human GAPDH
primers span the human GAPDH promoter sequence which is
known to be unmethylated. The genomic coordinates of the
regions used in the analysis based in NCBI build 36 are given. The
percentage recovery was calculated using the following formula
from Diagenode: % (meDNA-IP/Total Input): 2‘[(Ct (10%input)-
3.32) -Ct(meDNA-IP)]6100%. The percentage specificity was
calculated as: 1- (enrich unmeth/enrich meth)6100%.
(XLS)
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